Trial reportThe journal of nutrition, health & aging2009
Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly.
Trial report in The journal of nutrition, health & aging, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Megestrol acetate for treatment of anorexia-cachexia syndrome.The Cochrane database of systematic reviews · 2013Pooled it
- Comparison of the pharmacokinetic characteristics and bioequivalence between two nanosuspension formulations of megestrol acetate in healthy Korean male subjects.Translational and clinical pharmacology · 2024Article
- Anabolic Steroids in Fattening Food-Producing Animals-A Review.Animals : an open access journal from MDPI · 2022Review
- Anorexia of aging: a true geriatric syndrome.The journal of nutrition, health & aging · 2012Article
- Pharmacological interventions for geriatric cachexia: a narrative review of the literature.The journal of nutrition, health & aging · 2012Review
- Effects of anorexia on mortality among older adults receiving home care: an observation study.The journal of nutrition, health & aging · 2012Article
- Frailty: diagnosis and management.The journal of nutrition, health & aging · 2011Article
- Unintentional weight loss in older adults.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2011Review
- Assessment of malnutrition in older persons: a focus on the Mini Nutritional Assessment.The journal of nutrition, health & aging · 2011Article
- The challenge of appropriate identification and treatment of starvation, sarcopenia, and cachexia: a survey of Australian dietitians.Journal of nutrition and metabolism · 2011Article
- Clinical practice in nursing homes as a key for progress.The journal of nutrition, health & aging · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledThe aim of this review is to assess the efficacy and safety of megestrol acetate (MA) in geriatric cachexia. The paper presented here reviews a previously published study of MA use in 69 patients in a randomized double blind placebo-controlled trial. This paper will also address the underlying pathogenesis of cachexia (specifically, the role of cytokines) along with the use of MA, its mechanism of action and its side effects.
objectiveTo compare the effects of MA oral suspension (O.S.), 800 mg/day, versus placebo on weight in geriatric nursing home patients with weight loss or low body weight.
designTwelve weeks, randomized, double-blind, placebo-controlled trial with a 13-week follow-up period. PATIENTS: Northport VAMC Nursing home patients with weight loss of * 5% of usual body weight over the past 3 months, or body weight 20% below their ideal body weight.
interventionsPatients were randomly assigned to receive placebo or MA 800 mg/d for 12 weeks and were then followed for 13 weeks off treatment and mortality 4 years post treatment. MEASUREMENTS: Primary outcome- weight and appetite change. Secondary outcome-sense of well being, enjoyment of life, change in depression scale, laboratory nutrition parameters, energy intake counts, body composition, and adverse events.
resultsAt 12 weeks there were no significant differences in weight gain between treatment groups, while MA-treated patients reported significantly greater improvement in appetite, enjoyment of life, and well being. At week 25 (3 months after treatment), 61.9% of MA-treated patients had gained * 1.82 kg (4 lbs) compared to 21.7% of placebo patients. There was no difference in survival between MA and placebo groups. Considering possible confounders, higher initial IL-6, initial TNFR-p75 levels, and final neutrophil percentage were associated with elevated mortality, whereas higher initial pre-albumin, initial albumin, final pre-albumin, final albumin and final weight gain were associated with decreased death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.